bioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG
Rancoderm GmbH has been acquired by Rose Investment- und Beteiligungs AG to secure the funding required for the final development and market approval of its medical device DermaPro. The acquisition will enable Rancoderm to bring DermaPro to market readiness and launch it as a certified medical product for broad distribution.
Rancoderm is a German biotechnology company that develops innovative therapeutic solutions for chronic wounds. Its core focus is DermaPro, a novel active ingredient system designed to treat difficult-to-heal skin wounds such as diabetic foot syndrome and leg ulcers. A subsidiary of bioXXmed AG, Rancoderm is responsible for the research, clinical development and forthcoming market approval of this medical device, which has the potential to significantly improve wound healing outcomes.
Rose Investment- und Beteiligungs, based in Altenstadt, Hesse, is a German stock corporation focused on acquiring stakes in companies in the pharmaceutical, biotechnology and alternative energy sectors. The company also operates solar power plants, finances companies in these sectors and manages their activities.
bioXXmed is a publicly listed German investment company active in biotechnology and medical technology. The company invests in businesses developing innovative therapies and medical devices, particularly for chronic wound care and regenerative diseases. bioXXmed holds stakes in Rancoderm and DermaTools Biotech GmbH, supporting their research, development and regulatory approval processes for new active ingredients and therapeutic concepts.
Oaklins’ team in Germany acted as the lead advisor to bioXXmed and its management throughout the transaction. Given the target’s distressed stage, the process was time-critical, and a strategic buyer was identified within the required timeframe.
Talk to the deal team
Related deals
MEDIK Hospital Design Group has been acquired by STERIS
The private shareholders of MEDIK Hospital Design Group have sold their shares to STERIS plc. Together, MEDIK and STERIS will expand their offerings for hospitals and ambulatory surgery centers worldwide. MEDIK’s solutions ideally complement STERIS’ existing portfolio, enabling the combined group to strengthen its position as a leading provider of turnkey room solutions in surgical and IPT environments. The MEDIK management team will actively support the next phase of growth.
Learn moreBanook, backed by Motion Equity, has acquired Fluidda
Banook Group has acquired Fluidda NV, marking a strategic expansion into advanced in-silico trials and respiratory disease modeling. Combining Banook’s expertise in cardiac safety and clinical data services with Fluidda’s AI-driven respiratory analytics creates a powerful, integrated platform. This deal strengthens Banook’s position in the contract research organization (CRO) sector, offering pharmaceutical clients broader, technology-enabled solutions to drive drug development and reduce costs.
Learn moreSLT has been acquired by Indutrade
SLT S.r.l. has been acquired by Indutrade AB and will be integrated into the group’s life science business area. The transaction is Indutrade’s fifth acquisition in 2025 and is expected to have a marginally positive impact on the group’s earnings per share.
Learn more